KeyBank National Association’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $385K | Sell |
3,060
-502
| -14% | -$63.1K | ﹤0.01% | 879 |
|
|
2025
Q1 | $394K | Buy |
3,562
+467
| +15% | +$51.7K | ﹤0.01% | 856 |
|
|
2024
Q4 | $422K | Sell |
3,095
-493
| -14% | -$67.3K | ﹤0.01% | 856 |
|
|
2024
Q3 | $413K | Buy |
3,588
+531
| +17% | +$61.2K | ﹤0.01% | 866 |
|
|
2024
Q2 | $421K | Buy |
3,057
+1,435
| +88% | +$198K | ﹤0.01% | 801 |
|
|
2024
Q1 | $224K | Sell |
1,622
-2,008
| -55% | -$277K | ﹤0.01% | 1017 |
|
|
2023
Q4 | $478K | Sell |
3,630
-399
| -10% | -$52.6K | ﹤0.01% | 760 |
|
|
2023
Q3 | $453K | Buy |
4,029
+315
| +8% | +$35.4K | ﹤0.01% | 729 |
|
|
2023
Q2 | $350K | Sell |
3,714
-1,939
| -34% | -$183K | ﹤0.01% | 831 |
|
|
2023
Q1 | $572K | Sell |
5,653
-1,036
| -15% | -$105K | ﹤0.01% | 648 |
|
|
2022
Q4 | $799K | Sell |
6,689
-876
| -12% | -$105K | ﹤0.01% | 520 |
|
|
2022
Q3 | $803K | Sell |
7,565
-219
| -3% | -$23.2K | ﹤0.01% | 501 |
|
|
2022
Q2 | $759K | Buy |
7,784
+1,031
| +15% | +$101K | ﹤0.01% | 527 |
|
|
2022
Q1 | $633K | Sell |
6,753
-2,521
| -27% | -$236K | ﹤0.01% | 642 |
|
|
2021
Q4 | $790K | Buy |
9,274
+7
| +0.1% | +$596 | ﹤0.01% | 661 |
|
|
2021
Q3 | $889K | Buy |
9,267
+1,143
| +14% | +$110K | ﹤0.01% | 598 |
|
|
2021
Q2 | $791K | Sell |
8,124
-538
| -6% | -$52.4K | ﹤0.01% | 644 |
|
|
2021
Q1 | $842K | Sell |
8,662
-1,223
| -12% | -$119K | ﹤0.01% | 637 |
|
|
2020
Q4 | $947K | Sell |
9,885
-42
| -0.4% | -$4.02K | ﹤0.01% | 545 |
|
|
2020
Q3 | $955K | Buy |
9,927
+4,868
| +96% | +$468K | 0.01% | 497 |
|
|
2020
Q2 | $617K | Buy |
+5,059
| New | +$617K | ﹤0.01% | 614 |
|